AU2012222074A1 - Chalcone derivatives as Nrf2 activators - Google Patents

Info

Publication number

AU2012222074A1

AU2012222074A1 AU2012222074A AU2012222074A AU2012222074A1 AU 2012222074 A1 AU2012222074 A1 AU 2012222074A1 AU 2012222074 A AU2012222074 A AU 2012222074A AU 2012222074 A AU2012222074 A AU 2012222074A AU 2012222074 A1 AU2012222074 A1 AU 2012222074A1

Authority

AU

Australia

Prior art keywords

och

disease

compound

nrf2

group

Prior art date

2011-02-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 title claims abstract description 199
• 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 title claims abstract description 198
• 150000001788 chalcone derivatives Chemical class 0.000 title description 32
• 239000012190 activator Substances 0.000 title description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 118
• 150000001875 compounds Chemical class 0.000 claims abstract description 112
• 238000000034 method Methods 0.000 claims abstract description 109
• 201000010099 disease Diseases 0.000 claims abstract description 61
• 208000035475 disorder Diseases 0.000 claims abstract description 57
• 230000001105 regulatory effect Effects 0.000 claims abstract description 42
• 239000003246 corticosteroid Substances 0.000 claims abstract description 37
• 230000036542 oxidative stress Effects 0.000 claims abstract description 37
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
• 230000037361 pathway Effects 0.000 claims abstract description 31
• 208000004235 neutropenia Diseases 0.000 claims abstract description 29
• 208000019155 Radiation injury Diseases 0.000 claims abstract description 23
• 210000001185 bone marrow Anatomy 0.000 claims abstract description 23
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 18
• 238000002512 chemotherapy Methods 0.000 claims abstract description 15
• 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 13
• 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 12
• 208000028867 ischemia Diseases 0.000 claims abstract description 8
• 230000007812 deficiency Effects 0.000 claims abstract description 7
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
• 208000026278 immune system disease Diseases 0.000 claims abstract description 7
• 206010010356 Congenital anomaly Diseases 0.000 claims abstract description 6
• 208000017442 Retinal disease Diseases 0.000 claims abstract description 6
• 206010038923 Retinopathy Diseases 0.000 claims abstract description 6
• 230000005784 autoimmunity Effects 0.000 claims abstract description 6
• 208000016245 inborn errors of metabolism Diseases 0.000 claims abstract description 6
• 208000017169 kidney disease Diseases 0.000 claims abstract description 6
• 208000032839 leukemia Diseases 0.000 claims abstract description 6
• 230000004043 responsiveness Effects 0.000 claims abstract description 6
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 74
• 230000014509 gene expression Effects 0.000 claims description 73
• 210000004027 cell Anatomy 0.000 claims description 69
• 108090000623 proteins and genes Proteins 0.000 claims description 66
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 62
• 230000000694 effects Effects 0.000 claims description 59
• 150000003839 salts Chemical class 0.000 claims description 44
• 239000003795 chemical substances by application Substances 0.000 claims description 39
• 230000006378 damage Effects 0.000 claims description 39
• 108700032225 Antioxidant Response Elements Proteins 0.000 claims description 35
• -1 CF 3 Inorganic materials 0.000 claims description 32
• 208000006673 asthma Diseases 0.000 claims description 32
• 210000004072 lung Anatomy 0.000 claims description 32
• 230000004054 inflammatory process Effects 0.000 claims description 31
• 206010061218 Inflammation Diseases 0.000 claims description 30
• 230000006698 induction Effects 0.000 claims description 28
• 210000001519 tissue Anatomy 0.000 claims description 26
• 208000014674 injury Diseases 0.000 claims description 25
• 208000027418 Wounds and injury Diseases 0.000 claims description 24
• 230000005855 radiation Effects 0.000 claims description 21
• 230000003394 haemopoietic effect Effects 0.000 claims description 20
• 208000011580 syndromic disease Diseases 0.000 claims description 19
• 230000004071 biological effect Effects 0.000 claims description 18
• 125000003545 alkoxy group Chemical group 0.000 claims description 17
• 229910052739 hydrogen Inorganic materials 0.000 claims description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 208000015181 infectious disease Diseases 0.000 claims description 15
• 201000006417 multiple sclerosis Diseases 0.000 claims description 15
• 210000002540 macrophage Anatomy 0.000 claims description 14
• 230000002685 pulmonary effect Effects 0.000 claims description 13
• 210000002889 endothelial cell Anatomy 0.000 claims description 12
• 206010014561 Emphysema Diseases 0.000 claims description 11
• 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 11
• 230000027455 binding Effects 0.000 claims description 11
• 230000001580 bacterial effect Effects 0.000 claims description 10
• 230000030833 cell death Effects 0.000 claims description 10
• 239000002245 particle Substances 0.000 claims description 10
• 206010016654 Fibrosis Diseases 0.000 claims description 9
• 206010040047 Sepsis Diseases 0.000 claims description 9
• 230000001154 acute effect Effects 0.000 claims description 9
• 230000004761 fibrosis Effects 0.000 claims description 9
• 230000002496 gastric effect Effects 0.000 claims description 9
• 230000002103 transcriptional effect Effects 0.000 claims description 9
• 230000004075 alteration Effects 0.000 claims description 8
• 210000002919 epithelial cell Anatomy 0.000 claims description 8
• 238000001959 radiotherapy Methods 0.000 claims description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
• 208000024891 symptom Diseases 0.000 claims description 8
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 7
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
• 208000024340 acute graft versus host disease Diseases 0.000 claims description 7
• 239000003242 anti bacterial agent Substances 0.000 claims description 7
• 206010006451 bronchitis Diseases 0.000 claims description 7
• 208000007451 chronic bronchitis Diseases 0.000 claims description 7
• 230000004968 inflammatory condition Effects 0.000 claims description 7
• 230000000968 intestinal effect Effects 0.000 claims description 7
• 208000037906 ischaemic injury Diseases 0.000 claims description 7
• 230000004682 mucosal barrier function Effects 0.000 claims description 7
• 210000000056 organ Anatomy 0.000 claims description 7
• 208000032843 Hemorrhage Diseases 0.000 claims description 6
• 208000027625 autoimmune inner ear disease Diseases 0.000 claims description 6
• 230000005764 inhibitory process Effects 0.000 claims description 6
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
• 208000036065 Airway Remodeling Diseases 0.000 claims description 5
• 208000024827 Alzheimer disease Diseases 0.000 claims description 5
• 208000034309 Bacterial disease carrier Diseases 0.000 claims description 5
• 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims description 5
• 241000606768 Haemophilus influenzae Species 0.000 claims description 5
• 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
• 230000003115 biocidal effect Effects 0.000 claims description 5
• 230000005779 cell damage Effects 0.000 claims description 5
• KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 4
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 4
• 206010012735 Diarrhoea Diseases 0.000 claims description 4
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 4
• 201000004681 Psoriasis Diseases 0.000 claims description 4
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
• 206010047700 Vomiting Diseases 0.000 claims description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
• 229950000210 beclometasone dipropionate Drugs 0.000 claims description 4
• 208000034158 bleeding Diseases 0.000 claims description 4
• 230000000740 bleeding effect Effects 0.000 claims description 4
• 210000000988 bone and bone Anatomy 0.000 claims description 4
• 229960004436 budesonide Drugs 0.000 claims description 4
• 230000015556 catabolic process Effects 0.000 claims description 4
• 230000007278 cognition impairment Effects 0.000 claims description 4
• 229960003957 dexamethasone Drugs 0.000 claims description 4
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 230000003511 endothelial effect Effects 0.000 claims description 4
• 229960000676 flunisolide Drugs 0.000 claims description 4
• 229960000289 fluticasone propionate Drugs 0.000 claims description 4
• WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 4
• 229940047650 haemophilus influenzae Drugs 0.000 claims description 4
• 229960004584 methylprednisolone Drugs 0.000 claims description 4
• 230000004770 neurodegeneration Effects 0.000 claims description 4
• 229960005205 prednisolone Drugs 0.000 claims description 4
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
• 229960004618 prednisone Drugs 0.000 claims description 4
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 4
• 210000004872 soft tissue Anatomy 0.000 claims description 4
• 208000004998 Abdominal Pain Diseases 0.000 claims description 3
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
• 206010002961 Aplasia Diseases 0.000 claims description 3
• 201000006474 Brain Ischemia Diseases 0.000 claims description 3
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
• 241000588655 Moraxella catarrhalis Species 0.000 claims description 3
• 206010028116 Mucosal inflammation Diseases 0.000 claims description 3
• 201000010927 Mucositis Diseases 0.000 claims description 3
• 206010033661 Pancytopenia Diseases 0.000 claims description 3
• 208000018737 Parkinson disease Diseases 0.000 claims description 3
• 206010035664 Pneumonia Diseases 0.000 claims description 3
• 206010035742 Pneumonitis Diseases 0.000 claims description 3
• 206010039710 Scleroderma Diseases 0.000 claims description 3
• 206010040070 Septic Shock Diseases 0.000 claims description 3
• 241000191967 Staphylococcus aureus Species 0.000 claims description 3
• 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
• 206010046851 Uveitis Diseases 0.000 claims description 3
• 206010008118 cerebral infarction Diseases 0.000 claims description 3
• 210000004207 dermis Anatomy 0.000 claims description 3
• 229940112141 dry powder inhaler Drugs 0.000 claims description 3
• 210000002615 epidermis Anatomy 0.000 claims description 3
• 208000033065 inborn errors of immunity Diseases 0.000 claims description 3
• 206010025135 lupus erythematosus Diseases 0.000 claims description 3
• 229940071648 metered dose inhaler Drugs 0.000 claims description 3
• 210000003097 mucus Anatomy 0.000 claims description 3
• 210000003205 muscle Anatomy 0.000 claims description 3
• 239000006199 nebulizer Substances 0.000 claims description 3
• 230000001537 neural effect Effects 0.000 claims description 3
• 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 3
• 230000036303 septic shock Effects 0.000 claims description 3
• 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
• 230000029663 wound healing Effects 0.000 claims description 3
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
• 208000004232 Enteritis Diseases 0.000 claims description 2
• 241000709661 Enterovirus Species 0.000 claims description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
• 101150038307 Gclm gene Proteins 0.000 claims description 2
• 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 claims description 2
• 208000023105 Huntington disease Diseases 0.000 claims description 2
• 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
• 201000002832 Lewy body dementia Diseases 0.000 claims description 2
• 201000009906 Meningitis Diseases 0.000 claims description 2
• 206010054949 Metaplasia Diseases 0.000 claims description 2
• 206010028813 Nausea Diseases 0.000 claims description 2
• 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
• 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
• 108091000054 Prion Proteins 0.000 claims description 2
• 206010063562 Radiation skin injury Diseases 0.000 claims description 2
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
• 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
• 208000028990 Skin injury Diseases 0.000 claims description 2
• 201000005010 Streptococcus pneumonia Diseases 0.000 claims description 2
• 230000001363 autoimmune Effects 0.000 claims description 2
• 206010014599 encephalitis Diseases 0.000 claims description 2
• 201000006370 kidney failure Diseases 0.000 claims description 2
• 230000015689 metaplastic ossification Effects 0.000 claims description 2
• 230000008693 nausea Effects 0.000 claims description 2
• 201000004931 neurofibromatosis Diseases 0.000 claims description 2
• 230000004942 nuclear accumulation Effects 0.000 claims description 2
• 238000013518 transcription Methods 0.000 claims description 2
• 230000035897 transcription Effects 0.000 claims description 2
• 241000701161 unidentified adenovirus Species 0.000 claims description 2
• 230000008673 vomiting Effects 0.000 claims description 2
• QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
• 101100393844 Caenorhabditis elegans gst-3 gene Proteins 0.000 claims 1
• 101100266755 Cyanidium caldarium ycf39 gene Proteins 0.000 claims 1
• 101001071611 Dictyostelium discoideum Glutathione reductase Proteins 0.000 claims 1
• 102100027186 Extracellular superoxide dismutase [Cu-Zn] Human genes 0.000 claims 1
• 101710191461 F420-dependent glucose-6-phosphate dehydrogenase Proteins 0.000 claims 1
• 101150005894 GCLC gene Proteins 0.000 claims 1
• 101710155861 Glucose-6-phosphate 1-dehydrogenase Proteins 0.000 claims 1
• 101710174622 Glucose-6-phosphate 1-dehydrogenase, chloroplastic Proteins 0.000 claims 1
• 101710137456 Glucose-6-phosphate 1-dehydrogenase, cytoplasmic isoform Proteins 0.000 claims 1
• 101000836222 Homo sapiens Extracellular superoxide dismutase [Cu-Zn] Proteins 0.000 claims 1
• 101001071608 Homo sapiens Glutathione reductase, mitochondrial Proteins 0.000 claims 1
• 206010062018 Inborn error of metabolism Diseases 0.000 claims 1
• 101100449771 Musca domestica Gst3 gene Proteins 0.000 claims 1
• 101100410801 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pxr-1 gene Proteins 0.000 claims 1
• 101000655985 Plasmodium falciparum (isolate FCH-5) Thioredoxin reductase Proteins 0.000 claims 1
• 102000029797 Prion Human genes 0.000 claims 1
• 101000772462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Thioredoxin reductase 1 Proteins 0.000 claims 1
• 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims 1
• 210000003027 ear inner Anatomy 0.000 claims 1
• 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 claims 1
• 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 claims 1
• 239000012678 infectious agent Substances 0.000 claims 1
• 206010022000 influenza Diseases 0.000 claims 1
• 230000000302 ischemic effect Effects 0.000 claims 1
• 210000004400 mucous membrane Anatomy 0.000 claims 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
• 108010045815 superoxide dismutase 2 Proteins 0.000 claims 1
• 229960005294 triamcinolone Drugs 0.000 claims 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
• 101150008351 ycf3 gene Proteins 0.000 claims 1
• 208000001019 Inborn Errors Metabolism Diseases 0.000 abstract description 5
• 208000015978 inherited metabolic disease Diseases 0.000 abstract description 5
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 174
• 241000699670 Mus sp. Species 0.000 description 81
• SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 78
• 238000005481 NMR spectroscopy Methods 0.000 description 77
• DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 72
• 235000005513 chalcones Nutrition 0.000 description 72
• 150000001789 chalcones Chemical class 0.000 description 68
• 239000003963 antioxidant agent Substances 0.000 description 49
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 44
• SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 44
• 238000011282 treatment Methods 0.000 description 44
• 235000006708 antioxidants Nutrition 0.000 description 43
• 230000015572 biosynthetic process Effects 0.000 description 42
• 239000003981 vehicle Substances 0.000 description 42
• 230000003078 antioxidant effect Effects 0.000 description 37
• 238000003786 synthesis reaction Methods 0.000 description 37
• 230000004913 activation Effects 0.000 description 35
• 101710152212 Glutamate-cysteine ligase regulatory subunit Proteins 0.000 description 32
• 239000007787 solid Substances 0.000 description 32
• 101710095135 NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 29
• 102100033398 Glutamate-cysteine ligase regulatory subunit Human genes 0.000 description 28
• 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 28
• 230000001965 increasing effect Effects 0.000 description 25
• 230000004083 survival effect Effects 0.000 description 25
• 239000000203 mixture Substances 0.000 description 24
• 239000003642 reactive oxygen metabolite Substances 0.000 description 23
• SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 22
• 201000011510 cancer Diseases 0.000 description 22
• 239000003814 drug Substances 0.000 description 22
• 230000001404 mediated effect Effects 0.000 description 22
• 229960005559 sulforaphane Drugs 0.000 description 22
• 235000015487 sulforaphane Nutrition 0.000 description 22
• 230000003110 anti-inflammatory effect Effects 0.000 description 20
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 18
• 230000004044 response Effects 0.000 description 18
• 102000004190 Enzymes Human genes 0.000 description 17
• 108090000790 Enzymes Proteins 0.000 description 17
• 206010073306 Exposure to radiation Diseases 0.000 description 17
• 230000006870 function Effects 0.000 description 15
• 230000034994 death Effects 0.000 description 14
• 231100000517 death Toxicity 0.000 description 14
• 239000003921 oil Substances 0.000 description 14
• HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 13
• 102000002737 Heme Oxygenase-1 Human genes 0.000 description 13
• 108010018924 Heme Oxygenase-1 Proteins 0.000 description 13
• 102000040945 Transcription factor Human genes 0.000 description 13
• 108091023040 Transcription factor Proteins 0.000 description 13
• 230000001419 dependent effect Effects 0.000 description 13
• 239000012039 electrophile Substances 0.000 description 13
• 230000003389 potentiating effect Effects 0.000 description 13
• 235000018102 proteins Nutrition 0.000 description 13
• 102000004169 proteins and genes Human genes 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
• 239000002253 acid Substances 0.000 description 12
• 229940079593 drug Drugs 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 230000006907 apoptotic process Effects 0.000 description 11
• 235000019504 cigarettes Nutrition 0.000 description 11
• 230000001120 cytoprotective effect Effects 0.000 description 11
• 230000007423 decrease Effects 0.000 description 11
• 230000005713 exacerbation Effects 0.000 description 11
• 230000019491 signal transduction Effects 0.000 description 11
• DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 11
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
• 150000003254 radicals Chemical class 0.000 description 10
• 229940124597 therapeutic agent Drugs 0.000 description 10
• 108060001084 Luciferase Proteins 0.000 description 9
• 208000037883 airway inflammation Diseases 0.000 description 9
• 238000005882 aldol condensation reaction Methods 0.000 description 9
• 239000003054 catalyst Substances 0.000 description 9
• 239000012627 chemopreventive agent Substances 0.000 description 9
• 229940124443 chemopreventive agent Drugs 0.000 description 9
• 210000000813 small intestine Anatomy 0.000 description 9
• 239000000779 smoke Substances 0.000 description 9
• 125000001424 substituent group Chemical group 0.000 description 9
• 238000005160 1H NMR spectroscopy Methods 0.000 description 8
• 239000005089 Luciferase Substances 0.000 description 8
• 210000001132 alveolar macrophage Anatomy 0.000 description 8
• 239000002585 base Substances 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 230000002113 chemopreventative effect Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
• 230000002757 inflammatory effect Effects 0.000 description 8
• 150000002576 ketones Chemical group 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 208000019693 Lung disease Diseases 0.000 description 7
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 7
• 230000010085 airway hyperresponsiveness Effects 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
• 235000018417 cysteine Nutrition 0.000 description 7
• 238000001784 detoxification Methods 0.000 description 7
• 239000002158 endotoxin Substances 0.000 description 7
• 210000000265 leukocyte Anatomy 0.000 description 7
• 229920006008 lipopolysaccharide Polymers 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 210000000440 neutrophil Anatomy 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 230000035882 stress Effects 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• 208000035143 Bacterial infection Diseases 0.000 description 6
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 230000002378 acidificating effect Effects 0.000 description 6
• 150000001299 aldehydes Chemical class 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 208000022362 bacterial infectious disease Diseases 0.000 description 6
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
• VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
• 231100000433 cytotoxic Toxicity 0.000 description 6
• 230000001472 cytotoxic effect Effects 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 201000002491 encephalomyelitis Diseases 0.000 description 6
• 230000001771 impaired effect Effects 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 238000010172 mouse model Methods 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 230000004792 oxidative damage Effects 0.000 description 6
• 230000000242 pagocytic effect Effects 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 230000000069 prophylactic effect Effects 0.000 description 6
• 230000035945 sensitivity Effects 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 230000000451 tissue damage Effects 0.000 description 6
• 208000001395 Acute radiation syndrome Diseases 0.000 description 5
• 241000073677 Changea Species 0.000 description 5
• 101150027051 HO1 gene Proteins 0.000 description 5
• 102100028006 Heme oxygenase 1 Human genes 0.000 description 5
• 101100451279 Homo sapiens HMOX1 gene Proteins 0.000 description 5
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 5
• 108091054455 MAP kinase family Proteins 0.000 description 5
• 102000043136 MAP kinase family Human genes 0.000 description 5
• 108010058846 Ovalbumin Proteins 0.000 description 5
• 206010068142 Radiation sickness syndrome Diseases 0.000 description 5
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
• 239000000370 acceptor Substances 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 230000000078 anti-malarial effect Effects 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 230000003833 cell viability Effects 0.000 description 5
• 230000005754 cellular signaling Effects 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 229960001334 corticosteroids Drugs 0.000 description 5
• 230000003013 cytotoxicity Effects 0.000 description 5
• 231100000135 cytotoxicity Toxicity 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 208000027866 inflammatory disease Diseases 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 210000005087 mononuclear cell Anatomy 0.000 description 5
• 238000010606 normalization Methods 0.000 description 5
• 102000039446 nucleic acids Human genes 0.000 description 5
• 108020004707 nucleic acids Proteins 0.000 description 5
• 150000007523 nucleic acids Chemical class 0.000 description 5
• 229940092253 ovalbumin Drugs 0.000 description 5
• 239000007800 oxidant agent Substances 0.000 description 5
• 230000001590 oxidative effect Effects 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 229920001184 polypeptide Polymers 0.000 description 5
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 238000011084 recovery Methods 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 231100000827 tissue damage Toxicity 0.000 description 5
• 208000037816 tissue injury Diseases 0.000 description 5
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
• FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 4
• NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 102000005720 Glutathione transferase Human genes 0.000 description 4
• 108010070675 Glutathione transferase Proteins 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 102000002933 Thioredoxin Human genes 0.000 description 4
• 239000013566 allergen Substances 0.000 description 4
• 201000009961 allergic asthma Diseases 0.000 description 4
• 230000000202 analgesic effect Effects 0.000 description 4
• 230000000843 anti-fungal effect Effects 0.000 description 4
• 230000002927 anti-mitotic effect Effects 0.000 description 4
• 239000003430 antimalarial agent Substances 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 238000004820 blood count Methods 0.000 description 4
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 4
• 230000001767 chemoprotection Effects 0.000 description 4
• 230000007123 defense Effects 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 229930003935 flavonoid Natural products 0.000 description 4
• 150000002215 flavonoids Chemical class 0.000 description 4
• 235000017173 flavonoids Nutrition 0.000 description 4
• 238000003304 gavage Methods 0.000 description 4
• 229960003180 glutathione Drugs 0.000 description 4
• 150000003278 haem Chemical class 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 4
• 230000016273 neuron death Effects 0.000 description 4
• 230000008506 pathogenesis Effects 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 235000017807 phytochemicals Nutrition 0.000 description 4
• 229930000223 plant secondary metabolite Natural products 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 230000008439 repair process Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 238000003107 structure activity relationship analysis Methods 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• 108060008226 thioredoxin Proteins 0.000 description 4
• 229940094937 thioredoxin Drugs 0.000 description 4
• 239000011701 zinc Substances 0.000 description 4
• OEGOGTZGMYUYAH-BJMVGYQFSA-N (e)-1-(4-methoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=CC(C(F)(F)F)=C1 OEGOGTZGMYUYAH-BJMVGYQFSA-N 0.000 description 3
• AETKQQBRKSELEL-UHFFFAOYSA-N 1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one Chemical class OC1=CC=CC=C1C(=O)C=CC1=CC=CC=C1 AETKQQBRKSELEL-UHFFFAOYSA-N 0.000 description 3
• 208000032484 Accidental exposure to product Diseases 0.000 description 3
• FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 3
• 238000011740 C57BL/6 mouse Methods 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• 102000006587 Glutathione peroxidase Human genes 0.000 description 3
• 108700016172 Glutathione peroxidases Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102100039999 Histone deacetylase 2 Human genes 0.000 description 3
• 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 101150116862 KEAP1 gene Proteins 0.000 description 3
• 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 3
• 108010057466 NF-kappa B Proteins 0.000 description 3
• 102000003945 NF-kappa B Human genes 0.000 description 3
• 101710114687 Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 108091007960 PI3Ks Proteins 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 102000007456 Peroxiredoxin Human genes 0.000 description 3
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 101001109714 Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1 Proteins 0.000 description 3
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 238000006069 Suzuki reaction reaction Methods 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 231100000818 accidental exposure Toxicity 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 150000001413 amino acids Chemical group 0.000 description 3
• 230000002790 anti-mutagenic effect Effects 0.000 description 3
• 229940121375 antifungal agent Drugs 0.000 description 3
• 230000001640 apoptogenic effect Effects 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000008512 biological response Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 239000006227 byproduct Substances 0.000 description 3
• WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 150000001768 cations Chemical class 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 230000001332 colony forming effect Effects 0.000 description 3
• 238000009833 condensation Methods 0.000 description 3
• 230000005494 condensation Effects 0.000 description 3
• 235000012754 curcumin Nutrition 0.000 description 3
• 239000004148 curcumin Substances 0.000 description 3
• 229940109262 curcumin Drugs 0.000 description 3
• 230000016396 cytokine production Effects 0.000 description 3
• VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
• 239000003596 drug target Substances 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 239000003344 environmental pollutant Substances 0.000 description 3
• 230000006353 environmental stress Effects 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 238000003818 flash chromatography Methods 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 150000004820 halides Chemical class 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000008821 health effect Effects 0.000 description 3
• 230000011132 hemopoiesis Effects 0.000 description 3
• 230000013632 homeostatic process Effects 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 238000002493 microarray Methods 0.000 description 3
• 230000000116 mitigating effect Effects 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• 230000009456 molecular mechanism Effects 0.000 description 3
• 230000007886 mutagenicity Effects 0.000 description 3
• 231100000299 mutagenicity Toxicity 0.000 description 3
• 229930014626 natural product Natural products 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 210000003024 peritoneal macrophage Anatomy 0.000 description 3
• 108030002458 peroxiredoxin Proteins 0.000 description 3
• 230000002974 pharmacogenomic effect Effects 0.000 description 3
• SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 description 3
• SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 208000037920 primary disease Diseases 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 229940124554 radiomitigator Drugs 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 230000000241 respiratory effect Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 230000000391 smoking effect Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 238000005556 structure-activity relationship Methods 0.000 description 3
• 150000003573 thiols Chemical class 0.000 description 3
• 230000017423 tissue regeneration Effects 0.000 description 3
• 230000005945 translocation Effects 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• OTELYLKBYAVJEK-JXMROGBWSA-N (e)-1-(2,4-dimethoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1C(F)(F)F OTELYLKBYAVJEK-JXMROGBWSA-N 0.000 description 2
• MHAYHHVYWNSFCJ-RMKNXTFCSA-N (e)-1-(2,4-dimethoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=CC(C(F)(F)F)=C1 MHAYHHVYWNSFCJ-RMKNXTFCSA-N 0.000 description 2
• IBERQIQSQYUQQP-BJMVGYQFSA-N (e)-1-(2,4-dimethoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 IBERQIQSQYUQQP-BJMVGYQFSA-N 0.000 description 2
• ZRDCNUALRUCCPA-DHZHZOJOSA-N (e)-1-(2,4-dimethoxyphenyl)-3-phenylprop-2-en-1-one Chemical compound COC1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1 ZRDCNUALRUCCPA-DHZHZOJOSA-N 0.000 description 2
• QASUCCHCBAQYKR-ZHACJKMWSA-N (e)-1-(2,6-dimethoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC(OC)=C1C(=O)\C=C\C1=CC=CC=C1C(F)(F)F QASUCCHCBAQYKR-ZHACJKMWSA-N 0.000 description 2
• YNPQEYHYEHQARW-MDZDMXLPSA-N (e)-1-(2,6-dimethoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC(OC)=C1C(=O)\C=C\C1=CC=CC(C(F)(F)F)=C1 YNPQEYHYEHQARW-MDZDMXLPSA-N 0.000 description 2
• GQYUGVHXXLYWSA-DHZHZOJOSA-N (e)-1-(2,6-dimethoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC(OC)=C1C(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 GQYUGVHXXLYWSA-DHZHZOJOSA-N 0.000 description 2
• BDZOPPCXQXPRKH-ZHACJKMWSA-N (e)-1-(2-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC=C1C(=O)\C=C\C1=CC=CC=C1C(F)(F)F BDZOPPCXQXPRKH-ZHACJKMWSA-N 0.000 description 2
• PGGXQGGMPTUUER-MDZDMXLPSA-N (e)-1-(2-methoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC=C1C(=O)\C=C\C1=CC=CC(C(F)(F)F)=C1 PGGXQGGMPTUUER-MDZDMXLPSA-N 0.000 description 2
• ZXIWVMHUOOBDMQ-DHZHZOJOSA-N (e)-1-(2-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC=C1C(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 ZXIWVMHUOOBDMQ-DHZHZOJOSA-N 0.000 description 2
• GDJKIXHMSLEBEP-VAWYXSNFSA-N (e)-1-(2-methoxyphenyl)-3-phenylprop-2-en-1-one Chemical compound COC1=CC=CC=C1C(=O)\C=C\C1=CC=CC=C1 GDJKIXHMSLEBEP-VAWYXSNFSA-N 0.000 description 2
• BJOWDZIHLBFCDO-VQHVLOKHSA-N (e)-1-(3,4-dimethoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1C(F)(F)F BJOWDZIHLBFCDO-VQHVLOKHSA-N 0.000 description 2
• VBKATESFIPAUQG-SOFGYWHQSA-N (e)-1-(3,4-dimethoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)\C=C\C1=CC=CC(C(F)(F)F)=C1 VBKATESFIPAUQG-SOFGYWHQSA-N 0.000 description 2
• DJUDWUHRZBILKP-CSKARUKUSA-N (e)-1-(3,4-dimethoxyphenyl)-3-phenylprop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1 DJUDWUHRZBILKP-CSKARUKUSA-N 0.000 description 2
• UPKRPKNJCSFWOR-CMDGGOBGSA-N (e)-1-(3,5-dimethoxyphenyl)-3-phenylprop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C(=O)\C=C\C=2C=CC=CC=2)=C1 UPKRPKNJCSFWOR-CMDGGOBGSA-N 0.000 description 2
• UAHVTPOMQNJCJU-MDZDMXLPSA-N (e)-1-(3-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC(C(=O)\C=C\C=2C(=CC=CC=2)C(F)(F)F)=C1 UAHVTPOMQNJCJU-MDZDMXLPSA-N 0.000 description 2
• SDYJWWHBLGGKJR-CMDGGOBGSA-N (e)-1-(3-methoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=CC(C(=O)\C=C\C=2C=C(C=CC=2)C(F)(F)F)=C1 SDYJWWHBLGGKJR-CMDGGOBGSA-N 0.000 description 2
• YBUUDNGHUKBXSG-ZHACJKMWSA-N (e)-1-(3-methoxyphenyl)-3-phenylprop-2-en-1-one Chemical compound COC1=CC=CC(C(=O)\C=C\C=2C=CC=CC=2)=C1 YBUUDNGHUKBXSG-ZHACJKMWSA-N 0.000 description 2
• VAXLEWGXMBDXEN-NYYWCZLTSA-N (e)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 VAXLEWGXMBDXEN-NYYWCZLTSA-N 0.000 description 2
• NUNGHCGIWAQKCC-ZHACJKMWSA-N (e)-1-phenyl-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound FC(F)(F)C1=CC=CC=C1\C=C\C(=O)C1=CC=CC=C1 NUNGHCGIWAQKCC-ZHACJKMWSA-N 0.000 description 2
• MLTBAKXFRXZFTO-MDZDMXLPSA-N (e)-1-phenyl-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)C=2C=CC=CC=2)=C1 MLTBAKXFRXZFTO-MDZDMXLPSA-N 0.000 description 2
• QZMAQARJRMCAPU-DHZHZOJOSA-N (e)-1-phenyl-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C(=O)C1=CC=CC=C1 QZMAQARJRMCAPU-DHZHZOJOSA-N 0.000 description 2
• DTYLTVAPPXGTNT-CSKARUKUSA-N (e)-3-(2-nitrophenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=C(OC)C(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1[N+]([O-])=O DTYLTVAPPXGTNT-CSKARUKUSA-N 0.000 description 2
• ANPMSQPDCXKUJG-PKNBQFBNSA-N (e)-3-phenyl-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=C(OC)C(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1 ANPMSQPDCXKUJG-PKNBQFBNSA-N 0.000 description 2
• DRGVZVJDZOMQAI-MDZDMXLPSA-N (e)-3-phenyl-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(OC)=C1C(=O)\C=C\C1=CC=CC=C1 DRGVZVJDZOMQAI-MDZDMXLPSA-N 0.000 description 2
• HJRVQVGPAQZDPJ-MDZDMXLPSA-N (e)-3-phenyl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=C(OC)C(OC)=CC(C(=O)\C=C\C=2C=CC=CC=2)=C1 HJRVQVGPAQZDPJ-MDZDMXLPSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• ZTKPNSXSOUTJFJ-UHFFFAOYSA-N 1,2-diphenylprop-2-en-1-one Chemical class C=1C=CC=CC=1C(=C)C(=O)C1=CC=CC=C1 ZTKPNSXSOUTJFJ-UHFFFAOYSA-N 0.000 description 2
• KJFRSZASZNLCDF-UHFFFAOYSA-N 1,5-benzothiazepine Chemical class S1C=CC=NC2=CC=CC=C12 KJFRSZASZNLCDF-UHFFFAOYSA-N 0.000 description 2
• GMODFQAQVHNPNU-VAWYXSNFSA-N 2',6'-dimethoxychalcone Chemical compound COC1=CC=CC(OC)=C1C(=O)\C=C\C1=CC=CC=C1 GMODFQAQVHNPNU-VAWYXSNFSA-N 0.000 description 2
• AETKQQBRKSELEL-ZHACJKMWSA-N 2'-hydroxychalcone Chemical class OC1=CC=CC=C1C(=O)\C=C\C1=CC=CC=C1 AETKQQBRKSELEL-ZHACJKMWSA-N 0.000 description 2
• KJHHAPASNNVTSN-KPKJPENVSA-N 4'-Methoxychalcone Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1 KJHHAPASNNVTSN-KPKJPENVSA-N 0.000 description 2
• WBAKHFLMHRJDMB-UHFFFAOYSA-N 6-(3-methylbut-2-enyl)-2-phenyl-2,3-dihydrochromen-4-one Chemical class C1C(=O)C2=CC(CC=C(C)C)=CC=C2OC1C1=CC=CC=C1 WBAKHFLMHRJDMB-UHFFFAOYSA-N 0.000 description 2
• RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 2
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
• 208000007416 Aberrant Crypt Foci Diseases 0.000 description 2
• KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
• 101000889837 Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC 100138 / K1) Protein CysO Proteins 0.000 description 2
• 208000000884 Airway Obstruction Diseases 0.000 description 2
• 241001506979 Alpinia conchigera Species 0.000 description 2
• 241000048176 Astronium urundeuva Species 0.000 description 2
• TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
• 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
• 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
• 101100313164 Caenorhabditis elegans sea-1 gene Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 208000003322 Coinfection Diseases 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 230000004568 DNA-binding Effects 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
• 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 108010063907 Glutathione Reductase Proteins 0.000 description 2
• 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 2
• 102100033044 Glutathione peroxidase 2 Human genes 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 240000004670 Glycyrrhiza echinata Species 0.000 description 2
• 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
• 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
• 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 102000003964 Histone deacetylase Human genes 0.000 description 2
• 108090000353 Histone deacetylase Proteins 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 description 2
• 101000658584 Homo sapiens Transmembrane 4 L6 family member 5 Proteins 0.000 description 2
• 102100040524 Kelch-like ECH-associated protein 1 Human genes 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• 108010057281 Lipocalin 1 Proteins 0.000 description 2
• 206010067125 Liver injury Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 2
• 101000973779 Mus musculus NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• 108010002998 NADPH Oxidases Proteins 0.000 description 2
• 102000004722 NADPH Oxidases Human genes 0.000 description 2
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 101000971435 Oryctolagus cuniculus Protein kinase C gamma type Proteins 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 206010057249 Phagocytosis Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 108091027981 Response element Proteins 0.000 description 2
• 102000001332 SRC Human genes 0.000 description 2
• 108060006706 SRC Proteins 0.000 description 2
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
• 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 2
• 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 102100034898 Transmembrane 4 L6 family member 5 Human genes 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 241001424370 Zuccagnia punctata Species 0.000 description 2
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
• 150000008062 acetophenones Chemical class 0.000 description 2
• 229960004308 acetylcysteine Drugs 0.000 description 2
• 230000009798 acute exacerbation Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000036428 airway hyperreactivity Effects 0.000 description 2
• NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 description 2
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 230000006851 antioxidant defense Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000003190 augmentative effect Effects 0.000 description 2
• XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
• 244000052616 bacterial pathogen Species 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 150000003935 benzaldehydes Chemical class 0.000 description 2
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 238000012925 biological evaluation Methods 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 229940105329 carboxymethylcellulose Drugs 0.000 description 2
• 231100000357 carcinogen Toxicity 0.000 description 2
• 239000003183 carcinogenic agent Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000009104 chemotherapy regimen Methods 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 201000002758 colorectal adenoma Diseases 0.000 description 2
• 238000006482 condensation reaction Methods 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• IDASTKMEQGPVRR-UHFFFAOYSA-N cyclopenta-1,3-diene;zirconium(2+) Chemical class [Zr+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 IDASTKMEQGPVRR-UHFFFAOYSA-N 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000002939 deleterious effect Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000007120 differential activation Effects 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
• 229960002986 dinoprostone Drugs 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 229940000406 drug candidate Drugs 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000003203 everyday effect Effects 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 108091008053 gene clusters Proteins 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 125000004383 glucosinolate group Chemical group 0.000 description 2
• 230000036433 growing body Effects 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
• 231100000753 hepatic injury Toxicity 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 238000007489 histopathology method Methods 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 239000002955 immunomodulating agent Substances 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
• JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
• 235000008718 isoliquiritigenin Nutrition 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 229940010454 licorice Drugs 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 230000004199 lung function Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 230000003843 mucus production Effects 0.000 description 2
• 230000036457 multidrug resistance Effects 0.000 description 2
• 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 230000005937 nuclear translocation Effects 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 239000012038 nucleophile Substances 0.000 description 2
• 210000004287 null lymphocyte Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 125000001979 organolithium group Chemical group 0.000 description 2
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000008782 phagocytosis Effects 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 239000008389 polyethoxylated castor oil Substances 0.000 description 2
• 235000013824 polyphenols Nutrition 0.000 description 2
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 150000003138 primary alcohols Chemical class 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
• 230000004224 protection Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000004063 proteosomal degradation Effects 0.000 description 2
• 238000010791 quenching Methods 0.000 description 2
• 230000000171 quenching effect Effects 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 239000007845 reactive nitrogen species Substances 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000008844 regulatory mechanism Effects 0.000 description 2
• 230000001718 repressive effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000007086 side reaction Methods 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 125000000547 substituted alkyl group Chemical group 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 230000001839 systemic circulation Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 210000005090 tracheal smooth muscle Anatomy 0.000 description 2
• QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 210000000689 upper leg Anatomy 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• ITFBYYCNYVFPKD-FMIDTUQUSA-N (4ar,6ar,6as,6br,8as,12as,14bs)-8a-(imidazole-1-carbonyl)-4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-4a,5,6,6a,7,8,9,10,12,12a-decahydropicene-2-carbonitrile Chemical compound O=C([C@]12CCC(C[C@H]1[C@@H]1[C@@]([C@@]3(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]4(C)C3=CC1=O)C)(C)CC2)(C)C)N1C=CN=C1 ITFBYYCNYVFPKD-FMIDTUQUSA-N 0.000 description 1
• XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• MNJUUGHJXVRDQV-VQHVLOKHSA-N (e)-1-(2,5-dimethoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=C(OC)C(C(=O)\C=C\C=2C(=CC=CC=2)C(F)(F)F)=C1 MNJUUGHJXVRDQV-VQHVLOKHSA-N 0.000 description 1
• WQHSCKBQKVQPPT-SOFGYWHQSA-N (e)-1-(2,5-dimethoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC=C(OC)C(C(=O)\C=C\C=2C=C(C=CC=2)C(F)(F)F)=C1 WQHSCKBQKVQPPT-SOFGYWHQSA-N 0.000 description 1
• RARUAFIUCIRDKS-CSKARUKUSA-N (e)-1-(2,5-dimethoxyphenyl)-3-phenylprop-2-en-1-one Chemical compound COC1=CC=C(OC)C(C(=O)\C=C\C=2C=CC=CC=2)=C1 RARUAFIUCIRDKS-CSKARUKUSA-N 0.000 description 1
• TXUMXBIIHUMWSH-BQYQJAHWSA-N (e)-1-(3,5-dimethoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C(=O)\C=C\C=2C(=CC=CC=2)C(F)(F)F)=C1 TXUMXBIIHUMWSH-BQYQJAHWSA-N 0.000 description 1
• TZEZDGLZUHNGBK-VOTSOKGWSA-N (e)-1-(3,5-dimethoxyphenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C(=O)\C=C\C=2C=C(C=CC=2)C(F)(F)F)=C1 TZEZDGLZUHNGBK-VOTSOKGWSA-N 0.000 description 1
• IUJWAWAODSXWTI-DHZHZOJOSA-N (e)-1-(4-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC=CC=C1C(F)(F)F IUJWAWAODSXWTI-DHZHZOJOSA-N 0.000 description 1
• HHKVOYUYPYZFHJ-SOFGYWHQSA-N (e)-3-(3,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=CC=C1 HHKVOYUYPYZFHJ-SOFGYWHQSA-N 0.000 description 1
• GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 1
• VWHIOCBHCXLDKQ-SOFGYWHQSA-N 1,3,5-trimethoxy-2-[(E)-3-(2-nitrophenyl)prop-2-enyl]benzene Chemical compound COC1=CC(OC)=CC(OC)=C1C\C=C\C1=CC=CC=C1[N+]([O-])=O VWHIOCBHCXLDKQ-SOFGYWHQSA-N 0.000 description 1
• RARUAFIUCIRDKS-UHFFFAOYSA-N 1-(2,5-dimethoxyphenyl)-3-phenylprop-2-en-1-one Chemical class COC1=CC=C(OC)C(C(=O)C=CC=2C=CC=CC=2)=C1 RARUAFIUCIRDKS-UHFFFAOYSA-N 0.000 description 1
• HBBZSYPAQDRELN-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]prop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C=CC1=CC=C(N(C)C)C=C1 HBBZSYPAQDRELN-UHFFFAOYSA-N 0.000 description 1
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
• 101150029062 15 gene Proteins 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• JZKLXGZEUJUGIK-UHFFFAOYSA-N 2,3-dimethoxy-1,3-diphenylprop-2-en-1-one Chemical class COC(=C(C1=CC=CC=C1)OC)C(=O)C1=CC=CC=C1 JZKLXGZEUJUGIK-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• HHKVOYUYPYZFHJ-UHFFFAOYSA-N 3,4-Dihydroxychalcone Natural products C1=C(O)C(O)=CC=C1C=CC(=O)C1=CC=CC=C1 HHKVOYUYPYZFHJ-UHFFFAOYSA-N 0.000 description 1
• KTXHLWZQKQDFRF-UHFFFAOYSA-N 3-(2-nitrophenyl)-1-phenylprop-2-en-1-one Chemical class [O-][N+](=O)C1=CC=CC=C1C=CC(=O)C1=CC=CC=C1 KTXHLWZQKQDFRF-UHFFFAOYSA-N 0.000 description 1
• LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 102000004567 6-phosphogluconate dehydrogenase Human genes 0.000 description 1
• 108020001657 6-phosphogluconate dehydrogenase Proteins 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000010470 Ageusia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102100034452 Alternative prion protein Human genes 0.000 description 1
• 102000006941 Amino Acid Transport System X-AG Human genes 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 229910015900 BF3 Inorganic materials 0.000 description 1
• 239000002028 Biomass Substances 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 102000053028 CD36 Antigens Human genes 0.000 description 1
• 108010045374 CD36 Antigens Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 206010007269 Carcinogenicity Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 241001432959 Chernes Species 0.000 description 1
• 238000001353 Chip-sequencing Methods 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000032862 Clinical Deterioration Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000008857 Ferritin Human genes 0.000 description 1
• 108050000784 Ferritin Proteins 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 102000040718 GST family Human genes 0.000 description 1
• 108091071249 GST family Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 1
• 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
• 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
• 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
• 108091006151 Glutamate transporters Proteins 0.000 description 1
• 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
• 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
• 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 1
• 101710119052 Glutathione peroxidase 2 Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 101150044653 HMOX1 gene Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 102100029217 High affinity cationic amino acid transporter 1 Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101001034527 Homo sapiens Glutamate-cysteine ligase catalytic subunit Proteins 0.000 description 1
• 101000871129 Homo sapiens Glutathione peroxidase 2 Proteins 0.000 description 1
• 101100186933 Homo sapiens NFE2L2 gene Proteins 0.000 description 1
• 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
• 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 244000060701 Kaempferia pandurata Species 0.000 description 1
• 235000013412 Kaempferia pandurata Nutrition 0.000 description 1
• 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
• 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 241000283953 Lagomorpha Species 0.000 description 1
• 241000283986 Lepus Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 238000000134 MTT assay Methods 0.000 description 1
• 231100000002 MTT assay Toxicity 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
• 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 102000014736 Notch Human genes 0.000 description 1
• 108010070047 Notch Receptors Proteins 0.000 description 1
• 206010030216 Oesophagitis Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
• 238000004617 QSAR study Methods 0.000 description 1
• 101710149118 Quinone oxidoreductase 1 Proteins 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 230000006295 S-nitrosylation Effects 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 108091006229 SLC7A1 Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 206010053615 Thermal burn Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100023132 Transcription factor Jun Human genes 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 150000003998 acyclic ketones Chemical class 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 235000019666 ageusia Nutrition 0.000 description 1
• 239000013572 airborne allergen Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000036436 anti-hiv Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000002514 anti-leishmanial effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000842 anti-protozoal effect Effects 0.000 description 1
• 230000001754 anti-pyretic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000002221 antipyretic Substances 0.000 description 1
• 229940121383 antituberculosis agent Drugs 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 229930189065 blasticidin Natural products 0.000 description 1
• 239000006161 blood agar Substances 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 231100000260 carcinogenicity Toxicity 0.000 description 1
• 230000007670 carcinogenicity Effects 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000003570 cell viability assay Methods 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 208000029771 childhood onset asthma Diseases 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 229920005556 chlorobutyl Polymers 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 150000004777 chromones Chemical class 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000002153 concerted effect Effects 0.000 description 1
• 239000000039 congener Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 150000003997 cyclic ketones Chemical class 0.000 description 1
• 230000006196 deacetylation Effects 0.000 description 1
• 238000003381 deacetylation reaction Methods 0.000 description 1
• 230000012969 defense response to bacterium Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000005595 deprotonation Effects 0.000 description 1
• 238000010537 deprotonation reaction Methods 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 206010013781 dry mouth Diseases 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 231100001238 environmental toxicant Toxicity 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 208000006881 esophagitis Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• DRGVZVJDZOMQAI-UHFFFAOYSA-N flavokawain B Natural products COC1=CC(OC)=CC(OC)=C1C(=O)C=CC1=CC=CC=C1 DRGVZVJDZOMQAI-UHFFFAOYSA-N 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 238000004340 gradient COSY Methods 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000000777 hematopoietic system Anatomy 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 102000052142 human NFE2L2 Human genes 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 150000002483 hydrogen compounds Chemical class 0.000 description 1
• JEGUKCSWCFPDGT-UHFFFAOYSA-M hydroxide;hydrate Chemical compound O.[OH-] JEGUKCSWCFPDGT-UHFFFAOYSA-M 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 230000004047 hyperresponsiveness Effects 0.000 description 1
• 150000003949 imides Chemical class 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 230000007124 immune defense Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• 208000037798 influenza B Diseases 0.000 description 1
• 229940125369 inhaled corticosteroids Drugs 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
• 230000003859 lipid peroxidation Effects 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000010234 longitudinal analysis Methods 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 238000006241 metabolic reaction Methods 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 125000006682 monohaloalkyl group Chemical group 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 125000005484 neopentoxy group Chemical group 0.000 description 1
• 238000003012 network analysis Methods 0.000 description 1
• 230000009223 neuronal apoptosis Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
• 231100001083 no cytotoxicity Toxicity 0.000 description 1
• 231100000065 noncytotoxic Toxicity 0.000 description 1
• 230000002020 noncytotoxic effect Effects 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 101150075804 nqo1 gene Proteins 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000013618 particulate matter Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000006611 pharmacological activation Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 231100000719 pollutant Toxicity 0.000 description 1
• 125000006684 polyhaloalkyl group Polymers 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000002633 protecting effect Effects 0.000 description 1
• 230000009993 protective function Effects 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000005588 protonation Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000003247 radioactive fallout Substances 0.000 description 1
• 229940124553 radioprotectant Drugs 0.000 description 1
• 230000004223 radioprotective effect Effects 0.000 description 1
• 230000003537 radioprotector Effects 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000020874 response to hypoxia Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 102000035013 scavenger receptor class A Human genes 0.000 description 1
• 108091005451 scavenger receptor class A Proteins 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 208000013931 susceptibility to asthma Diseases 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 239000000814 tuberculostatic agent Substances 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 231100000054 whole-body exposure Toxicity 0.000 description 1
• 239000002676 xenobiotic agent Substances 0.000 description 1
• 230000002034 xenobiotic effect Effects 0.000 description 1
• 230000022814 xenobiotic metabolic process Effects 0.000 description 1